Recomgen Biotech

About:

Recomgen Biotech engages in R&D, production and sales of drugs.

Website: http://www.recomgenbio.com/

Top Investors: Guangzhou Financial Holding Fund Management, Wanlian Tianze, CSC Group, Nanhai Gangneng Fuel & Materials, Fuho Capital

Description:

Recomgen Biotech is an innovative biopharmaceutical company that focuses on large-scale serum-free continuous animal cell culture technology and the R&D of new biological drugs. Recomgen Biotech is working on developing rhTNK-tPA, a generation-specific thrombolytic drug that can be injected intravenously in a single dose, making it convenient for emergency treatment and out-of-hospital thrombolysis as needed. It improves the treatment rate, clinical benefit, and personal and societal medical burdens in patients with acute myocardial infarction who received thrombolytic therapy.